1-Aryl-3-(1H-imidazol-1-yl)propan-1-ol esters: synthesis, anti-Candidapotential and molecular modeling studies
Background An increased incidence of fungal infections, both invasive and superficial, has been witnessed over the last two decades. Candida species seem to be the main etiology of nosocomial fungal infections worldwide with Candida albicans , which is commensal in healthy individuals, accounting fo...
Gespeichert in:
Veröffentlicht in: | Chemistry Central journal 2013-10, Vol.7 (1), Article 168 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
An increased incidence of fungal infections, both invasive and superficial, has been witnessed over the last two decades.
Candida
species seem to be the main etiology of nosocomial fungal infections worldwide with
Candida albicans
, which is commensal in healthy individuals, accounting for the majority of invasive
Candida
infections with about 30-40% of mortality.
Results
New aromatic and heterocyclic esters
5a-k
of 1-aryl-3-(1
H
-imidazol-1-yl)propan-1-ols
4a-d
were successfully synthesized and evaluated for their anti-
Candida
potential. Compound
5a
emerged as the most active congener among the newly synthesized compounds
5a-k
with MIC value of 0.0833 μmol/mL as compared with fluconazole (MIC value >1.6325 μmol/mL). Additionally, molecular modeling studies were conducted on a set of anti-
Candida albicans
compounds.
Conclusion
The newly synthesized esters
5a-k
showed more potent anti-
Candida
activities than fluconazole. Compounds
7
and
8
revealed significant anti-
Candida albicans
activity and were able to effectively satisfy the proposed pharmacophore geometry, using the energy accessible conformers (E
conf
|
---|---|
ISSN: | 1752-153X 1752-153X |
DOI: | 10.1186/1752-153X-7-168 |